US obesity rates show first decline in a decade as GLP-1 drug use surges
New data suggests a potential turning point in the American obesity epidemic, driven by a quadrupling in weight-loss drug prescriptions, though experts warn it is too early to confirm a permanent trend reversal.
Obesity prevalence in the United States has recorded a decline for the first time in more than a decade, marking a significant shift after years of steady increase. A 2024 study by Benjamin Rader, an epidemiologist at Boston Children's Hospital and Harvard Medical School, analysed data from over 16 million adults and identified a drop in obesity rates in 2023. This finding is corroborated by the National Health and Nutrition Examination Survey, which also indicated a slight decline between 2021 and 2023.
The timing of this reduction coincides with a rapid expansion in the use of GLP-1 agonist medications, including Ozempic, Wegovy, and Zepbound. Prescriptions for these drugs, originally developed to treat Type 2 diabetes by mimicking intestinal hormones to promote fullness, more than quadrupled between 2021 and early 2026. Rader noted that while the impact of these medications was expected to appear in population data, he remains moderately confident that the drugs themselves are contributing to the observed weight loss.
Peminda Cabandugama, an endocrinologist and spokesperson for The Obesity Society, stated that there is strong evidence of a significant decline in obesity. In a written statement, he attributed the reduction to a confluence of factors, including the increased use of anti-obesity medications, post-pandemic behavioural changes, and heightened public awareness regarding weight management. However, he cautioned that it is still too early to determine whether this represents a true trend reversal or a temporary plateau.
Scepticism remains regarding the long-term sustainability of these improvements. A study by the Institute of Health Metrics and Evaluation (IHME) at the University of Washington predicts that obesity rates will rise again, potentially increasing from 42.5% in 2022 to 46.9% by 2035. The IHME authors argue that current prediction models may not fully account for the long-term effects of GLP-1 drugs, noting that only a small proportion of obese individuals currently use them and that many patients discontinue treatment within a year or regain weight.
Rader acknowledged that while the IHME predictions are not necessarily wrong, many models are based on pre-boom data and may overestimate the future burden of obesity. He warned that without more representative data, it is difficult to assess whether these medications will have a lasting effect on the general population. Despite the promising initial signs, he emphasised that obesity remains a complex chronic condition influenced by biological, genetic, social, and psychological factors.
The potential health outcomes of a sustained decline include improvements in cardiometabolic parameters, such as blood glucose levels, cardiovascular health, and fatty liver disease, which could ultimately reduce pressure on the healthcare system. Nevertheless, Rader stressed that the issue remains a major public health crisis requiring continued funding and attention, particularly given that GLP-1 drugs are not accessible to all Americans due to price and other barriers.
